Allogene Therapeutics (ALLO) investor relations material

Leadership transition and company overview

• Incoming CEO Zach Roberts will succeed David Chang, who will remain on the board and involved in company activities.

• The company has evolved since its 2018 launch, focusing on allogeneic cell therapy and organizational growth.

• Recent financing extends the cash runway to Q1 2029, supporting ongoing and future clinical milestones.

ALPHA3 study and cema-cel program

• ALPHA3 study targets MRD-positive large B-cell lymphoma patients post-first-line therapy, aiming to improve cure rates without overtreating those already cured.

• Interim data showed cema-cel cleared MRD in 58.3% of patients, with rapid and significant tumor DNA reduction by day 45.

• Safety profile is favorable, with most patients treated and managed as outpatients and no treatment-related hospitalizations.

• The study is designed for a 50% reduction in EFS events (hazard ratio 0.5), with interim analysis expected mid-next year and primary analysis in mid-2028.

• Market opportunity for cema-cel is estimated at $2.5–$3.5 billion in the US and EU5, with MRD testing expected to increase as actionable therapies become available.

Autoimmune program and pipeline progress

• ALLO-329, a dual-targeting CAR T for autoimmune diseases, is enrolling well with early clinical responses observed.

• The program targets both CD19 and CD70, aiming to address B cell dysfunction and underlying autoimmune pathogenesis.

• Next data update for ALLO-329 is planned for Q4, including higher dose cohorts and longer-term follow-up.